Skip to content
Parakho

Vineet Laboratories Ltd

NSE VINEETLABBSE 543298

Q4 FY26

Revenue
₹18.89 Cr
Profit after tax
₹1.22 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE and NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ4 FY26vs a year agoFY26
Revenue from operations18.89+34.21%59.40
Other income0.03−97.84%0.10
Total income18.92+22.40%59.50
Employee benefit expense1.20−10.93%4.10
Finance costs0.99+10.17%4.89
Depreciation & amortisation0.54−18.06%2.41
Total expenses17.93−32.81%58.22
Profit before tax0.99+108.86%1.28
Tax expense0.27+138.70%0.17
Profit after tax1.22+111.58%1.60
Total comprehensive income1.22+111.70%1.60
Earnings per share
Earnings per share, basic₹0.43₹1.00
Earnings per share, diluted₹0.43₹1.00

Q4 FY26 and FY26 — from the company’s filing with NSE. Source

Q4 FY25, the year-ago base — from the company’s filing with BSE. Source

Q4 FY26 results for every company Parakho holds

Earnings call

Vineet Laboratories Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 19 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.